Arrowhead Pharmaceuticals, Inc. (ARWR) Stock: Price, Forecast & Analyst Target
Arrowhead Pharmaceuticals, Inc. (ARWR) — MoonshotScore 12/100 (Weak band), calculated Nov 18, 2026. Price $43.11 (+0.28%), as of the Nov 18, 2026 trading session; market cap $6.09B.
Educational signal · not a buy or sell recommendation · How to read this
Arrowhead Pharmaceuticals, Inc. · ARWR · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Arrowhead Pharmaceuticals is an RNA interference drug developer whose economics currently come from collaboration-driven receipts while it spends heavily to advance a broad clinical pipeline. Reported revenue can surge without durable profitability, so the case hinges on whether clinical progress and launch preparation can create recurring product economics before development spending erodes the liquidity cushion.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Arrowhead Pharmaceuticals (ARWR)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Fragile; Valuation: Rich; Growth Durability: Shrinking; Momentum: Slipping.
- quarterly revenue $256M (Q4 FY2025, quarter ended Sep 2025)
- EPS beat 1 of the last 4 reports
- Altman Z 0.00 · Piotroski F 1
Holding back: weak fundamentals, balance-sheet strain, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 30 | Weak | |
| 26 | Weak | |
| 13 | Weak | |
| 13 | Weak | |
| 12 | Weak | |
| 12 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $43.11 | |
| Change on the day | +0.28% | |
| 52-week range | $37.06–$95.49 | |
| Market capitalisation | $6.09B | — |
| Price / earnings (trailing) | 51.18 | |
| Shares traded on the day | 2.42M | |
| Beta (volatility vs the S&P 500) | 1.37 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Arrowhead Pharmaceuticals (ARWR): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Arrowhead Pharmaceuticals (ARWR), and what does it report?
Short answer · as of
Arrowhead designs RNA interference therapies intended to silence disease-causing targets.
Research dated 2026-09-13.
It licenses or co-develops candidates with Janssen and Takeda while retaining an internal slate spanning liver, cardiometabolic, pulmonary, oncology and rare-disease programs.
The income statement does not follow prescription demand in a normal commercial rhythm. Revenue and gross profit have moved almost in lockstep, while revenue has swung from negligible to exceptionally large across reporting periods; reported sales therefore read as collaboration timing and program economics rather than a clean volume curve for marketed medicines.
What do the latest results show for Arrowhead Pharmaceuticals (ARWR)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $256M.
Research dated 2026-09-13.
The latest period brought revenue little changed from the preceding period, but the net loss deepened as research spending climbed and operating cash flow reversed from an inflow to a sizable outflow. Revenue surpassed consensus while earnings fell short, reinforcing that receipts and the cost base can move independently.
Management expects active study costs to moderate over time, yet it also plans continued spending on regulatory work, supply readiness for a potential sHTG launch and advancement of the broader pipeline. That is guidance about future cost behavior, not an achieved reduction; the latest research expense moved higher.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $256M | -$24M | — |
| Q1 FY2026 | $264M | $31M | $0.22 (diluted) |
| Q2 FY2026 | $74M | -$133M | -$0.93 (diluted) |
| Q3 FY2026 | $75M | -$194M | -$1.36 (diluted) |
What are the financial strengths and risks for Arrowhead Pharmaceuticals (ARWR)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Liquidity is the main defense: cash and short-term investments exceed total debt, leaving the company in a net cash position. Yet cash declined from the preceding period alongside a heavy operating outflow, and the latest loss shows how quickly capital can be consumed when receipts do not align with spending.
The calculated runway looks long because annualized cash use is dampened by prior inflows, while quarterly cash generation has been highly uneven. Sustained clinical execution without matching collaboration or product receipts would weaken that comfort; leverage and negative return measures make the burn trajectory more informative than the headline cash balance alone.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.00 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Arrowhead Pharmaceuticals (ARWR)?
Short answer · as of
Current published price targets run low $74.00 · high $126.00 · consensus $111.20 · median $117.50 against a quoted price of $43.11 (as of Nov 18, 2026).
Research dated 2026-09-13.
At the coming results, watch whether revenue remains around the subdued recent run rate, whether operating cash usage tracks the widening accounting loss and whether research spending has peaked. Near-term consensus anticipates continued losses and lower revenue, but the earnings history shows that estimates have been poor anchors for this lumpy model.
Operationally, watch regulatory progress and supply readiness around sHTG, followed by evidence that management’s promised study-cost moderation is emerging after the current fiscal period. The broad spread in longer-range revenue estimates shows how much future economics still depends on pipeline conversion rather than extrapolation from recent receipts.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q4 FY2025) was filed Nov 25, 2025 — 11 months ago.
Checked against the records this page reads, on the dates shown above.
How does Arrowhead Pharmaceuticals compare with its peers?
Short answer
Arrowhead Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Compared with a product-led biotechnology company, Arrowhead resembles a financed RNA interference portfolio: collaboration receipts can create profitable periods even while the research engine keeps spending. This makes revenue less repeatable but brings partner participation across a wide therapeutic slate.
Compared with a narrow-asset developer, Arrowhead spreads clinical exposure across targets and partners, although that breadth also sustains heavy research expense. Its cash position buys execution room; it does not turn episodic receipts into a commercial franchise or remove trial, regulatory and launch risk.
| Company | Price | Market value | Score |
|---|---|---|---|
| $95.05 Nov 18, 2026 | $7.47B | 98 5-pillar Nov 18, 2026 | |
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $41.37 Nov 18, 2026 | $4.53B | 84 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $95.74 Nov 18, 2026 | $6.49B | 67 5-pillar Nov 18, 2026 | |
| $13.76 Nov 18, 2026 | $4.83B | 67 5-pillar Nov 18, 2026 | |
| $124.86 Nov 18, 2026 | $5.27B | 66 5-pillar Nov 18, 2026 | |
| $156.23 Nov 18, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 | |
| Arrowhead Pharmaceuticals (ARWR) — this page | $43.11 | $6.09B | 12 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $74.00 – $126.00
- Consensus target
- $111.20
- Median target
- $117.50
Consensus record · Captured .
Measured against a quoted price of $43.11 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Aug 18, 2026
- Transactions
- 3
- Identified insiders
- 3
- Purchases
- 0
- Sales
- 2
- Other transactions
- 1
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ARWR in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ARWR in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Arrowhead Pharmaceuticals (ARWR)?
- ARWR: Commercial Momentum Builds Ahead of Potential Expansion into sHTG Market
- Could RNAi Trial Data Alter The Investment Case For Arrowhead Pharmaceuticals (ARWR)?
- Arrowhead Pharmaceuticals Announces Inducement Grants for New Employees
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Common Questions About ARWR (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does Arrowhead’s RNA interference revenue swing so sharply?
Licensing and co-development economics can arrive unevenly, while research spending continues through reporting periods. Revenue and earnings volatility therefore should not be read as changes in prescription demand.
What would sHTG supply readiness change for Arrowhead?
It would move Arrowhead deeper into regulatory and commercial preparation for a potential launch while broader pipeline spending continues. The useful evidence would be launch-related progress accompanied by economics that depend less on collaboration timing.
Can Arrowhead’s cash support ARO-AAT and ARO-XDH development?
Cash and short-term investments stand above debt, providing meaningful funding capacity for the pipeline. Highly variable operating cash flow makes the recent runway estimate a weak steady-state guide, however.
How does Olpasiran fit Arrowhead’s partnership model?
Olpasiran is among the RNA interference programs advanced beyond Arrowhead’s core internal slate, illustrating how the company can participate in candidate progression through external relationships. That structure broadens program exposure, while reported economics remain tied to collaboration events rather than a uniform product-sales stream.
What is the ARWR stock price today?
The last price recorded for Arrowhead Pharmaceuticals, Inc. (ARWR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ARWR price target?
The analyst consensus price target for Arrowhead Pharmaceuticals, Inc. (ARWR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 22 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold ARWR
Funds in our ETF coverage that list ARWR among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.